Curran Terrie

Average Profitability
28.29%
Insider Buys Quantity
2
Insider Buys Sum
$252,860.59
Insider Sells Quantity
6
Insider Sells Sum
$1.12M

Insider Activity of Curran Terrie

According to the SEC Form 4 filings, Curran Terrie, being in a position of

  1. President and Chief Executive at Phathom Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 50699 shares for $550,211,
    over all time since 2021-03-22, has bought 33419 shares for $252,861, and sold 70995 shares for $1.12M.

The largest purchase of all time was on 2022-05-13 and amounted to 20500 shares of Phathom Pharmaceuticals, Inc. for $151,835.

The largest sale of all time was on 2021-03-22 and amounted to 11513 shares of Phathom Pharmaceuticals, Inc. for $498,751.

Biography of Curran Terrie

No biography is available at this moment.

2024-07-15SalePhathom Pharmaceuticals, Inc.
PHAT
President and Chief Executive
33,848
0.0663%
$11.72$396,6990%
2024-03-22SalePhathom Pharmaceuticals, Inc.
PHAT
President and Chief Executive
16,851
0.0238%
$9.11$153,513+1.45%
2023-04-06PurchasePhathom Pharmaceuticals, Inc.
PHAT
President and Chief Executive
12,919
0.0318%
$7.82$101,025+34.68%
2023-03-01SalePhathom Pharmaceuticals, Inc.
PHAT
President and Chief Executive
1,436
0.0033%
$8.54$12,265+13.21%
2023-01-20SalePhathom Pharmaceuticals, Inc.
PHAT
President and Chief Executive
5,821
0.0134%
$8.20$47,729+20.09%
2022-11-21SalePhathom Pharmaceuticals, Inc.
PHAT
President and Chief Executive
1,526
0.0038%
$9.60$14,650+9.39%
2022-05-13PurchasePhathom Pharmaceuticals, Inc.
PHAT
President and Chief Executive
20,500
0.0497%
$7.41$151,835+21.9%
2021-03-22SalePhathom Pharmaceuticals, Inc.
PHAT
President and Chief Executive
11,513
0.0316%
$43.32$498,751-26.14%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.